aspirin and Coronary Thrombosis studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Coronary Thrombosis: Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.

Research Excerpts

Excerpt	Relevance	Reference
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."	9.14	Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
" Whether aspirin ameliorates this risk in patients with established coronary artery disease undergoing cardiac or noncardiac surgery is unknown."	8.95	Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis. ( Cooper, CJ; Husnain, M; Kanjwal, Y; Khan, AR; Khan, MS; Khuder, SA; Luni, FK; Riaz, H; Riaz, IB; Riaz, T; Taleb, M, 2017)
"Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention."	8.89	Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013)
"The following four studies were evaluated: the Coumadin Aspirin Reinfarction Study (CARS); the Combination Hemotherapy and Mortality Prevention (CHAMP) Study; the Warfarin, Aspirin Reinfarction Study (WARIS)-II; the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT)-2 Study."	8.82	[Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. ( Landmark, K; Madsen, S; Reikvam, A, 2003)
"This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy."	7.85	Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017)
"There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)."	7.81	Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015)
"This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy."	7.79	Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013)
"To determine the prognosis of patients with giant coronary aneurysms (GA) caused by Kawasaki disease (KD) treated with combined oral warfarin and aspirin."	7.75	Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease. ( Ayusawa, M; Higaki, T; Kudo, Y; Matsuishi, T; Matsumura, M; Miura, M; Nomura, Y; Ogawa, S; Suda, K, 2009)
" During pregnancy, aspirin prophylaxis was prescribed and followed by steroids after caesarian section."	7.73	[Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal]. ( Galicier, L; Guillevin, L; Meune, C; Salengro, E; Spaulding, C; Wahbi, K; Weber, S, 2005)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."	7.73	Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"According to the meta-analysis and the results of the two studies with the highest power, aspirin is effective in primary prevention of coronary heart disease."	7.72	[Primary prevention of coronary heart disease with aspirin]. ( Kübler, W, 2004)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."	7.72	Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
" We report the successful use of ticlopidine, together with aspirin, in a 7-month-old infant with Kawasaki disease complicated by a thrombus in a giant coronary aneurysm that failed to resolve with thrombolytic therapy."	7.70	Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. ( Baker, AL; Neufeld, EJ; Newburger, JW; O'Brien, M; Parness, IA; Sundel, RP, 2000)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."	6.74	Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
" Ongoing studies are challenging the current one-size-fits-all dosing strategy, but the preceding evaluation of platelet function assays has not been adequate."	6.48	Antiplatelet effect of aspirin in patients with coronary artery disease. ( Grove, EL, 2012)
"In secondary-prevention trials to treat unstable angina, which were performed in USA and Canada, the number of non-fatal myocardial infarctions was reduced by about 50 per cent."	6.38	Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin. ( Born, GV, 1990)
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h."	5.35	Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008)
"A patient with Kawasaki disease is reported who had a medium-sized CAA prematurely occluded with thrombi during regression, resulting in myocardial ischemia."	5.35	Accelerated thrombotic occlusion of a medium-sized coronary aneurysm in Kawasaki disease by the inhibitory effect of ibuprofen on aspirin. ( Kwon, K; Sohn, S, 2008)
"The present results are similar to those observed in clinical trials where administration of low-dose aspirin plus prasugrel was associated with a low rate of major bleeding and CV events."	5.34	Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome. ( Choi, JH; Chon, MK; Chun, KJ; Hwang, KW; Jung, SM; Kim, JH; Kim, JS; Lee, SH; Lee, SY; Park, YH, 2020)
"Coronary thrombosis was produced by insertion of a thrombogenic copper coil into the LAD of 40 anesthetized pigs."	5.30	Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran. ( Hatori, N; Mattsson, C; Nordlander, R; Rydén, L; Sjöquist, PO; Uriuda, Y; Wang, QD, 1998)
"Aspirin-treated dogs were not different from vehicle."	5.29	Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis. ( Cohen, DS; Dotson, R; Mathis, J; Olson, RW; Webb, RL, 1993)
"The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone."	5.24	Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017)
"The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents."	5.24	6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017)
"Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone."	5.24	Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017)
"In EES-treated subjects, significant reductions in stent thrombosis and MI and an increase in bleeding were observed with continued thienopyridine beyond 1 year compared with aspirin alone."	5.22	Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. ( Cohen, DJ; Cutlip, DE; Hermiller, JB; Hsieh, WH; Kereiakes, DJ; Krucoff, MW; Massaro, JM; Mauri, L; Steg, PG; Windecker, S; Yeh, RW, 2016)
"Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation."	5.22	6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016)
"The relationships between Q waves that appear during the acute phase of ST-elevation myocardial infarction (STEMI), clinical characteristics, ST-segment resolution (STRes), and clopidogrel therapy in patients treated with fibrinolysis are not well described."	5.19	Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. ( Cannon, CP; Gibson, CM; Giugliano, RP; Morrow, DA; Sabatine, MS; Scirica, BM; Sloan, S; Waks, JW; Wiviott, SD, 2014)
"Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models."	5.19	Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014)
"We screened 1277 patients to enroll 93 aspirin, 147 clopidogrel, and 23 dual poor responders, based on a point-of-care assay, who underwent elective coronary angioplasty at 10 European sites for stable or low-risk unstable coronary artery disease."	5.14	Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho ( Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P, 2009)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."	5.14	Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"We studied stent thrombosis in 4,607 patients with acute coronary syndromes who received a coronary stent as part of routine care during 2 trials of aspirin versus sibrafiban for secondary prevention."	5.10	Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). ( Berger, PB; Bhapkar, MV; Califf, RM; Harrington, RA; Moliterno, DJ; Newby, LK; Ohman, EM; Tolleson, TR; Topol, EJ; Van de Werf, F; Verheugt, FW; White, HD, 2003)
" Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine."	5.09	Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999)
"The presence of the Pl(A2) allele is associated with enhanced thrombin formation and an impaired antithrombotic action of aspirin, which might favor coronary thrombosis in the Pl(A2) carriers."	5.09	Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. ( Brummel, K; Mann, KG; Musial, J; Szczeklik, A; Undas, A, 2001)
"Twelve habitual smokers with stable coronary disease, on aspirin 325 mg/d, were studied immediately before and 5 minutes after smoking two cigarettes each."	5.08	Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. ( Hung, J; Lacoste, L; Lam, JY; Letchacovski, G, 1995)
" Whether aspirin ameliorates this risk in patients with established coronary artery disease undergoing cardiac or noncardiac surgery is unknown."	4.95	Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis. ( Cooper, CJ; Husnain, M; Kanjwal, Y; Khan, AR; Khan, MS; Khuder, SA; Luni, FK; Riaz, H; Riaz, IB; Riaz, T; Taleb, M, 2017)
"The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme."	4.90	Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014)
"Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention."	4.89	Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013)
"P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization."	4.88	Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? ( Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A, 2012)
"The clinical benefit of the combination of aspirin plus clopidogrel over aspirin alone to prevent recurrent events after acute coronary syndrome is obviously a key step of the past few years in the management of coronary artery disease."	4.84	[Management coronary syndrome in the acute phase]. ( Collet, JP; Montalescot, G, 2007)
"The purpose of this article was to determine the incidence of in-stent thrombosis (IST) after coronary stent implantation in patients with cocaine abuse."	4.84	Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature. ( Arora, R; Bahekar, A; Handa, K; Khosla, S; Khraisat, A; Singh, S; Trivedi, A, 2007)
"The following four studies were evaluated: the Coumadin Aspirin Reinfarction Study (CARS); the Combination Hemotherapy and Mortality Prevention (CHAMP) Study; the Warfarin, Aspirin Reinfarction Study (WARIS)-II; the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT)-2 Study."	4.82	[Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. ( Landmark, K; Madsen, S; Reikvam, A, 2003)
"The current standard of care for the treatment of arterial thrombosis includes anticoagulants and three classes of antiplatelet agents--aspirin, thienopyridines and glycoprotein IIb-IIIa antagonists."	4.82	Therapeutic approaches in arterial thrombosis. ( Andre, P; Conley, PB; Phillips, DR; Sinha, U, 2005)
"On the basis of this methodology, enoxaparin would appear to be more effective than placebo when added to aspirin in acute coronary syndromes."	4.81	Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control. ( Cruickshank, MK; Massel, D, 2002)
"We have reviewed some of the voluminous literature on the effects of aspirin combined with dipyridamole on coronary thrombosis."	4.78	Aspirin and dipyridamole and their limitations in the therapy of coronary artery disease. ( Folts, JD; Rowe, GG, 1990)
" In such patients, aspirin diminishes by about half the incidence of myocardial infarction and death."	4.77	Polypharmacologic interactions in the management of thrombosis. ( Born, GV, 1989)
" Case presentation A 66-year-old Japanese male patient received regorafenib for metastatic colorectal carcinoma and apixaban for deep vein thrombosis."	4.02	Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report. ( Matoba, S; Ookura, T; Shoji, K; Yanishi, K; Zen, K, 2021)
"In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin."	3.96	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. ( Alexander, JH; Aronson, R; Goodman, SG; Granger, CB; Lopes, RD; Mehran, R; Thomas, L; Vora, AN; Windecker, S; Wojdyla, D, 2020)
"The present study confirms the strong relationship of high platelet reactivity on clopidogrel to 2-year ischemic and bleeding outcomes after DES."	3.85	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. ( Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2017)
"This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy."	3.85	Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017)
"The initial EROSION study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion) demonstrated that patients with acute coronary syndrome caused by plaque erosion might be stabilized with aspirin and ticagrelor without stenting for ≤1 month."	3.85	EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report. ( Bryniarski, K; Hou, J; Hu, S; Jang, IK; Jia, H; Lee, H; Li, L; Liu, H; Ma, L; Sugiyama, T; Wang, C; Xing, L; Xu, M; Yamamoto, E; Yu, B; Zhang, S; Zhu, Y, 2017)
"In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding."	3.85	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. ( Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B, 2017)
" Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months."	3.85	Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. ( Apruzzese, PK; Cannon, CP; Cohen, DJ; Cutlip, DE; D'Agostino, RB; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017)
"Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)."	3.83	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016)
"There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)."	3.81	Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015)
"Patients with high PR on clopidogrel have a greater incidence of adverse ischemic events after stent implantation, whereas low PR may increase bleeding."	3.81	Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). ( Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parikh, PB; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K, 2015)
" This investigation aimed to evaluate the effect of hypothermia on the pharmacodynamic response of aspirin and clopidogrel in patients (n = 20) with ST elevation myocardial infarction undergoing primary PCI."	3.80	Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. ( Angiolillo, DJ; Ariza, A; Cequier, A; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Homs, S; Lorente, V; Marcano, AL; Rivera, K; Romaguera, R; Roura, G; Sánchez-Elvira, G; Sánchez-Salado, JC; Sosa, SG; Teruel, L, 2014)
"This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy."	3.79	Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013)
" We present a case of postoperative simultaneous left anterior descending and right coronary stent thrombosis that followed cessation of long-term aspirin therapy in a patient with stable coronary artery disease."	3.78	Simultaneous left anterior descending and right coronary stent thrombosis after aspirin withdrawal. ( Abdelmalak, HD; Camporesi, EM; Karlnoski, R; Mangar, D; Omar, HR, 2012)
" Thrombolysis in myocardial infarction (TIMI) 3 flow predicted a good outcome, whereas recurrent ischemia in hospital, prior aspirin therapy and discharge creatinine predicted a poor outcome; age alone was not an adverse prognostic factor."	3.76	Influence of age on long-term outcome after emergent percutaneous coronary intervention for ST-elevation myocardial infarction. ( Attia, J; Baker, F; Collins, N; Hatton, R; Hiew, C; McElduff, P; Narasimhan, S; O'Connor, S; Williams, T, 2010)
"To determine the prognosis of patients with giant coronary aneurysms (GA) caused by Kawasaki disease (KD) treated with combined oral warfarin and aspirin."	3.75	Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease. ( Ayusawa, M; Higaki, T; Kudo, Y; Matsuishi, T; Matsumura, M; Miura, M; Nomura, Y; Ogawa, S; Suda, K, 2009)
"To model the 2-year cost-effectiveness of secondary prevention with clopidogrel versus aspirin (acetylsalicylic acid) (ASS) in German patients with myocardial infarction (MI), ischaemic stroke (IS) or diagnosed with peripheral arterial disease (PAD), based on CAPRIE trial data and from the perspective of German third party payers (TPP)."	3.74	Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. ( Berger, K; Diener, HC; Hessel, F; Kreuzer, J; Smala, A, 2008)
" During pregnancy, aspirin prophylaxis was prescribed and followed by steroids after caesarian section."	3.73	[Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal]. ( Galicier, L; Guillevin, L; Meune, C; Salengro, E; Spaulding, C; Wahbi, K; Weber, S, 2005)
"We sought to assess the effect of sildenafil, a highly-specific type 5 phosphodiesterase (PDE5) inhibitor, on platelet-mediated cyclic coronary flow reductions occurring in a canine model of coronary thrombosis despite aspirin therapy."	3.73	Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis. ( Bloch, KD; Colon-Hernandez, P; Guerrero, JL; Lewis, GD; Semigran, MJ; Witzke, C, 2006)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."	3.73	Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"According to the meta-analysis and the results of the two studies with the highest power, aspirin is effective in primary prevention of coronary heart disease."	3.72	[Primary prevention of coronary heart disease with aspirin]. ( Kübler, W, 2004)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."	3.72	Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
"A 4-month-old girl with Kawasaki disease, large coronary artery aneurysms, and coronary thrombi was treated with standard therapy followed by abciximab, a platelet glycoprotein IIb/IIIa antagonist, in addition to standard heparin and warfarin sodium anticoagulation and low-dose aspirin."	3.70	Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease. ( Etheridge, SP; Minich, LL; Revenaugh, JR; Tani, LY, 1998)
" We report the successful use of ticlopidine, together with aspirin, in a 7-month-old infant with Kawasaki disease complicated by a thrombus in a giant coronary aneurysm that failed to resolve with thrombolytic therapy."	3.70	Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. ( Baker, AL; Neufeld, EJ; Newburger, JW; O'Brien, M; Parness, IA; Sundel, RP, 2000)
"To determine initial intravenous gammaglobulin (IVIG) treatment failures in Kawasaki disease (KD) and to report the outcome of retreatment and our use of pulse intravenous (IV) methylprednisolone and cyclophosphamide in patients with persistent KD."	3.70	Initial intravenous gammaglobulin treatment failure in Kawasaki disease. ( French, JW; Kahn, SJ; Sherry, DD; Wallace, CA, 2000)
" Those with acute myocardial infarction, radiolucent defects in coronary arteries suggestive of thrombus, and results that were not optimal after stent implantation were anticoagulated with warfarin and not Included in the study."	3.69	Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin. ( Aroney, CN; Bett, JH; McEniery, PT; Sankardas, MA, 1996)
"In conscious dogs with coronary thrombosis induced by electrical current, we assessed the impact on the rapidity of thrombolysis and the incidence of reocclusion of two types of adjunctive treatment given concomitantly with intravenous tissue-type plasminogen activator (t-PA): 1) inhibition of platelet function with a peptide mimetic antagonist of platelet glycoprotein IIb/IIIa receptors or with lysine acetylsalicylic acid (ASA) and 2) inhibition of thrombin activity with recombinant hirudin or with heparin."	3.68	Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. ( Abendschein, DR; Haskel, EJ; Prager, NA; Sobel, BE, 1991)
"Coronary thrombosis is known to provoke myocardial infarctions, but whether PWH have elevated thrombotic propensity is unknown."	2.90	Targeting thrombogenicity and inflammation in chronic HIV infection. ( Aberg, JA; Badimon, JJ; Cavanagh, K; Escolar, G; Heyison, A; O'Brien, MP; Okoroafor, I; Rodriguez, JC; Rodriguez-Caprio, G; Weinberg, A; Zafar, MU, 2019)
"Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation."	2.79	Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014)
" Following this randomized pilot study, it may be justified to perform a large-scale randomized study comparing 50- and 75-mg dosing of clopidogrel in Japanese patients undergoing coronary stent implantation."	2.79	Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. ( Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K, 2014)
"Aspirin was prescribed indefinitely, and a thienopyridine for at least six months."	2.78	Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. ( Claessen, BE; Dangas, GD; Mehran, R; Stone, GW; Xu, K, 2013)
" Two 7-day treatments were separated by 14-day washout periods: (a) PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later and (b) synchronous dosing of clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)."	2.78	Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. ( Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y, 2013)
"Pantoprazole treatment does not impair the efficacy of dual antiplatelet therapy in patients with SAP after PCI."	2.77	Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. ( Chmiel, A; Gąsior, Z; Gieszczyk, K; Haberka, M; Kunecki, M; Kyrcz-Krzemień, S; Lasota, B; Mizia, M; Mizia-Stec, K; Najda, J, 2012)
" (2) Clopidogrel may be under dosed in obese patients."	2.75	Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. ( Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2010)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."	2.74	Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
" Major adverse cardiac events (death, myocardial infarction, target lesion revascularization, and coronary artery bypass grafting) were observed at 30 days in 5 of 200 (2."	2.71	Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study. ( Ashby, DT; Aymong, ED; Fischell, T; Lansky, AJ; Leon, MB; Mehran, R; Narasimaiah, R; Siegel, R; Thomas, W; Whitworth, H; Wong, SC, 2003)
"Cilostazol is a potent antiplatelet agent with less serious side effects."	2.69	Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999)
"Aspirin alone at the low dose of 100 mg administered or the combination of coumadin and aspirin after high-pressure coronary stenting does not prevent adverse clinical events when ultrasound guidance is not used."	2.69	Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin after provisional coronary stenting: final and follow-up results of a randomized study. ( Barmeyer, J; Germing, A; Jäger, D; Lange, S; Lemke, B; Machraoui, A; von Dryander, S, 1999)
"Ticlopidine-plus-aspirin has become standard antiplatelet therapy for the prevention of thrombotic complications after coronary stenting."	2.69	Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. ( Aguirre, FV; Ligon, RW; Lucore, CL; Mishkel, GJ; Rocha-Singh, KJ, 1999)
" A new therapeutic regimen of ticlopidine and aspirin without further heparin after coronary stenting in patients without AMI has been shown to be safe and reduce the incidence of stent thrombosis."	2.69	A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. ( Chang, HW; Chen, MC; Fang, CY; Hang, CL; Hsieh, KY; Wu, CJ; Yip, HK, 2000)
"Ticlopidine therapy was discontinued in 1."	2.68	Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management. ( Bauters, C; Bedossa, M; Bertrand, ME; Bonnet, JL; Danchin, N; Grollier, G; Lablanche, JM; Leclercq, C; McFadden, EP; Vahanian, A; Van Belle, E, 1996)
"Dipyridamole was applied in 550 interventions (455 interventions in men, 95 interventions in women, age = 59."	2.68	[Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study]. ( Heidland, UE; Heintzen, MP; Kelm, M; Klimek, WJ; Leschke, M; Michel, CJ; Schwartzkopff, B; Strauer, BE; Vester, EG, 1997)
"Aspirin was effective only in complex and less severe lesions (< 90% stenosis)."	2.67	Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis. ( de Swart, H; Lie, KI; Meyer, A; Michels, HR; van der Pol, JM; van Eenige, MJ; Veen, G; Verheugt, FW; Werter, CJ, 1993)
"Indeed, Kawasaki disease is no longer a rare cause of acute coronary syndrome presenting in young adults."	2.53	Kawasaki Disease. ( Burns, JC; Newburger, JW; Takahashi, M, 2016)
" The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events."	2.50	Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014)
"It is essential to define/quantify the postoperative blood loss that precludes administration of early aspirin."	2.50	Who might benefit from early aspirin after coronary artery surgery? ( Bilkhu, R; Gukop, P; Gutman, N; Karapanagiotidis, GT, 2014)
" Ongoing studies are challenging the current one-size-fits-all dosing strategy, but the preceding evaluation of platelet function assays has not been adequate."	2.48	Antiplatelet effect of aspirin in patients with coronary artery disease. ( Grove, EL, 2012)
" For example, increasing the dosage of aspirin or alternative antiplatelet drugs are potential therapeutic concepts, but these require careful future investigation."	2.44	Aspirin "resistance". ( Hohlfeld, T; Weber, AA; Zimmermann, N, 2008)
" In contrast to aspirin, the response to clopidogrel is highly variable and reflects the bioavailability of the active metabolite and not "resistance" of the receptor to inhibition."	2.44	Aspirin and clopidogrel resistance. ( Fitzgerald, DJ; Maree, A, 2007)
"To prevent coronary thrombosis, long-term anti-thrombosis using anti-platelet drugs, such as aspirin, dipyridamole, ticlopidine, clopidogrel, and abciximab, with or without warfarin is recommended by official guidelines."	2.44	[Prevention of thrombosis of coronary aneurysms in patients with a history of Kawasaki disease]. ( Ishii, M; Kudo, Y; Matsuishi, T; Suda, K; Sugawara, Y, 2008)
"The etiology of Kawasaki disease (KD) remains unknown despite several years of dedicated research in this direction."	2.43	Current perspectives on Kawasaki disease. ( Gupta-Malhotra, M; Rao, PS, 2005)
"Fibrinolysis is the reference treatment for most myocardial infarctions with ST-segment elevation; alternatives are angioplasty, with or without stent."	2.43	New anticoagulants in ischemic heart disease. ( Verheugt, FW, 2005)
" Clinicians should ensure that patients at high risk of atherothrombosis (>3% risk over 5 years) are compliant with aspirin therapy and are taking the correct dosage (75-150 mg/day)."	2.42	Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. ( Eikelboom, JW; Hankey, GJ, 2004)
"Cilostazol is a vasodilating antiplatelet agent that reversibly inhibits platelet aggregation induced by many factors."	2.41	Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. ( El-Beyrouty, C; Spinler, SA, 2001)
" Clinical trial evidence is now available to show that the LMWH enoxaparin, in a dosage of 1."	2.40	Treatment options in unstable angina: a clinical update. ( Antman, EM; Fox, KA, 1998)
"The final common pathway to the coronary thrombosis underlying ACS involves the aggregation of platelets mediated by the binding of soluble fibrinogen to the platelet receptor glycoprotein (GP) IIb-IIIa."	2.40	Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. ( Harrington, RA, 1999)
"Aspirin is a weak antiplatelet agent; however, its side effects can cause in tolerance, and between 15% and 45% of patients are resistant to its antiplatelet effects."	2.40	The thienopyridines in coronary artery disease. ( Berger, PB, 1999)
" All patients undergoing PTCA should receive adequate antiplatelet therapy, including aspirin, and heparin with dosing monitored by activated clotting times (ACT)."	2.39	Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty. ( Barry, WH; Boston, DR; Malouf, A, 1996)
"In secondary-prevention trials to treat unstable angina, which were performed in USA and Canada, the number of non-fatal myocardial infarctions was reduced by about 50 per cent."	2.38	Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin. ( Born, GV, 1990)
"Acute myocardial infarction is most commonly initiated by fissuring of an atheromatous plaque."	2.38	Coronary thrombosis: pathogenesis and prevention. ( Born, GV, 1990)
"4 young male KD patients had coronary aneurysm (CAA) complicated with total 7 occurrences of central thrombosis."	1.72	Treatment of thrombosis in KD Patients using tissue plasminogen activator: a single center study. ( Chu, Y; Ma, Q; Wang, C; Wang, H; Xu, Y; Yu, X, 2022)
"Major bleeding was a significant correlate of DAPT ANA within 6 months."	1.42	Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. ( Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R, 2015)
"Cangrelor is an intravenous ATP analog that directly, selectively and reversibly inhibits P2Y12 receptors on platelets."	1.40	Cangrelor for treatment during percutaneous coronary intervention. ( Dobesh, PP; Oestreich, JH, 2014)
" Use of β-adrenergic blockers is recommended in most guidelines, but the clinical trials to support this recommendation were performed more than 30 years ago, and routine long-term use may not be relevant to modern treatment, except when there is cardiac failure or left ventricular dysfunction."	1.40	Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. ( Judkins, C; Thompson, AG; Thompson, PL, 2014)
"Routine follow-up has revealed no recurrence of symptoms."	1.40	The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis. ( BinBrek, AS; Mahmoud, WE; Murugesan, V; Rajani, AR, 2014)
"To prevent coronary thrombosis, long term thromboprophylaxis using anti-platelet drugs, such as aspirin, dipyridamole, ticlopidine, clopidogrel, and abciximab, with or without warfarin is recommended by official guidelines."	1.40	[Thromboprophylaxis in patients with coronary aneurysms caused by Kawasaki disease]. ( Suda, K, 2014)
" In conclusion, compared with immediate PCI, d-PCI after ATT in selected, stabilized patients with ACS and a large intracoronary thrombus and without an urgent need for revascularization is probably safe and associated with a reduction in thrombotic burden, angiographic complications, and the need of revascularization."	1.39	Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. ( Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ, 2013)
"Stroke is an important clinical problem and some strokes are caused by a cardiac thrombus."	1.39	64-MDCT can depict the thrombi expanded from the left lower pulmonary vein to the left atrium in the patient with angina pectoris. ( Takeuchi, H, 2013)
"Most of acute coronary thrombosis in KD occurred in LAD."	1.39	[Six Kawasaki disease patients with acute coronary artery thrombosis]. ( Gong, FQ; Liang, YG; Luo, JP; Qi, YQ; Wang, W; Zhou, SL, 2013)
"Aspirin was substituted with indobufen (64."	1.39	Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen. ( Carlino, M; Chieffo, A; Colombo, A; Ferri, L; Godino, C; Ielasi, A; Latib, A; Montorfano, M, 2013)
"Bleeding has emerged as a predictor of early and late mortality after percutaneous coronary interventions."	1.38	Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. ( Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O, 2012)
"Systemic lupus erythematosus is a chronic inflammatory disorder that predisposes to acute coronary thrombosis."	1.37	Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy. ( Matthai, WH; Patel, PJ; Untereker, WJ, 2011)
" The effect of aspirin dosing was evaluated using χ(2) , Cochran-Mantel-Haenszel, and homogeneity testing."	1.37	Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. ( Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S, 2011)
"The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target lesion revascularization [TLR]) and safe (stent thrombosis <1%) at 9 months."	1.36	Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)
"The underlying disease was paroxysmal nocturnal hemoglobinuria (PNH), a stem cell defect characterized by episodes of complement-induced hemolysis and thromboembolic events."	1.36	[Between thrombosis and bleeding - a case of paroxysmal nocturnal hemoglobinuria]. ( Reinhart, WH, 2010)
" In 199 patients treated with DAT alone (control group) and 103 patients treated with rabeprazole plus DAT (rabeprazole group), we examined the incidences of GI bleeding and major adverse cardiac events (MACE) including stent thrombosis."	1.36	[Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. ( Chubachi, H; Ikee, R; Miyasaka, Y; Saito, S; Yasu, T, 2010)
"Only aspirin was reinitiated three days after the procedure."	1.36	Late bare metal stent thrombosis. ( Erkol, A; Kırma, C; Oduncu, V; Tanboğa, IH, 2010)
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h."	1.35	Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008)
"Myocardial infarction is common in patients with a history of coronary artery disease."	1.35	[Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents]. ( Erdmann, E; Flesch, M; Krausgrill, B, 2008)
"Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P)."	1.35	Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. ( Beauzile, P; Bonello, L; Gavini, R; Gurbel, P; Kaneshige, K; Kent, K; Pichard, AD; Pinto Slottow, TL; Satler, LF; Scheinowitz, M; Suddath, WO; Sushinsky, SJ; Tantry, U; Torguson, R; Waksman, R; Xue, Z, 2009)
"A patient with Kawasaki disease is reported who had a medium-sized CAA prematurely occluded with thrombi during regression, resulting in myocardial ischemia."	1.35	Accelerated thrombotic occlusion of a medium-sized coronary aneurysm in Kawasaki disease by the inhibitory effect of ibuprofen on aspirin. ( Kwon, K; Sohn, S, 2008)
"Aspirin is a powerful anti-platelet drug widely used in patients with coronary atherosclerosis, but its side effects and especially its toxicity for gastrointestinal tract limit its usefulness in specific groups of patients."	1.34	Nitric oxide-releasing aspirin: will it say NO to atherothrombosis? ( Antoniades, C; Stefanadis, C; Tousoulis, D, 2007)
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up."	1.34	Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007)
"ticlopidine) treatment remained the sole predictor of TSO (OR: 5."	1.33	Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. ( Amit, G; Cafri, C; Gilutz, H; Ilia, R; Wolak, A; Zahger, D, 2005)
" An adequate dosage of ticlopidine (250 mg twice daily) and aspirin (100 mg/day) led to a lower rate of stent thrombosis (6 of 2,189 cases) than inadequate dosages or missing therapy (12 of 343 cases)."	1.32	Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis. ( Hambrecht, R; Hentschel, B; Hüttl, T; Lauer, B; Niebauer, J; Schuler, G; Sick, P; Thiele, H, 2003)
"Aspirin pretreatment increased the tongue-bleeding time, whereas the addition of CRL42796 or enoxaparin did not prolong bleeding time to a further degree."	1.32	Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, preven ( Driscoll, EM; Giboulot, TA; Hong, TT; Lucchesi, BR; Sherigill, A; White, AJ, 2003)
"Long-term management of patients with Kawasaki disease is tailored to the degree of coronary involvement; recommendations regarding antiplatelet and anticoagulant therapy, physical activity, follow-up assessment, and the appropriate diagnostic procedures to evaluate cardiac disease are classified according to risk strata."	1.32	Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. ( Baddour, LM; Baltimore, RS; Bolger, AF; Burns, JC; Falace, DA; Ferrieri, P; Gerber, MA; Gewitz, MH; Levison, ME; Newburger, JW; Pallasch, TJ; Shulman, ST; Takahashi, M; Tani, LY; Taubert, KA; Wilson, WR, 2004)
"Long-term management of patients with Kawasaki disease is tailored to the degree of coronary involvement; recommendations regarding antiplatelet and anticoagulant therapy, physical activity, follow-up assessment, and the appropriate diagnostic procedures to evaluate cardiac disease are classified according to risk strata."	1.32	Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. ( Baddour, LM; Baltimore, RS; Bolger, AF; Burns, JC; Falace, DA; Ferrieri, P; Gerber, MA; Gewitz, MH; Levison, ME; Newburger, JW; Pallasch, TJ; Shulman, ST; Takahashi, M; Tani, LY; Taubert, KA; Wilson, WR, 2004)
"2."	1.31	Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796. ( Driscoll, EM; Giboulot, TA; Hennan, JK; Hong, TT; Lucchesi, BR; Willens, DE, 2002)
"Pre-treatment with aspirin lessened the number of CFRs but did not reduce platelet accumulation in LAD myocardium (483+/-148%)."	1.31	Dynamic intracoronary thrombosis does not cause significant downstream platelet embolization. ( Barrabés, JA; Garcia-Dorado, D; Garcia-Lafuente, A; Puigfel, Y; Solares, J; Soler-Soler, J; Soriano, B; Trobo, L, 2000)
"In celecoxib-treated animals, vasodilation in response to arachidonic acid was reduced significantly compared with controls."	1.31	Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. ( Barrett, TD; Crofford, LJ; Driscoll, EM; Hennan, JK; Huang, J; Lucchesi, BR; Park, AM; Willens, DE, 2001)
"Reduced anticoagulation with antiplatelet therapy alone after coronary stenting, despite infrequent use of intravascular ultrasound, is an effective and safe strategy with a low rate of vascular complications, a relatively short hospital stay and a low incidence of clinical manifestations of stent thrombosis."	1.30	Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice. ( Buller, CE; Chauhan, A; Moscovich, MD; Penn, IM; Ricci, DR; Zubaid, M, 1997)
"completely abolished the experimental coronary thrombosis and prevented the exacerbation of coronary thrombosis by epinephrine 0."	1.30	Inhibition of platelet activity in vivo by amlodipine alone and combined with aspirin. ( Folts, JD, 1997)
"Coronary thrombosis was produced by insertion of a thrombogenic copper coil into the LAD of 40 anesthetized pigs."	1.30	Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran. ( Hatori, N; Mattsson, C; Nordlander, R; Rydén, L; Sjöquist, PO; Uriuda, Y; Wang, QD, 1998)
"Aspirin (30 mg) was given orally before experiment."	1.29	A new animal model of coronary thrombosis and effects of antithrombotic agents. ( Chen, Z; Fan, Y; Wang, P; Zhang, W, 1995)
"Occlusive coronary thrombosis was induced in 5 groups of 10 dogs by placing a copper coil into the left anterior descending coronary artery."	1.29	Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs. ( Arnout, J; Collen, D; Dol, F; Herbert, JM; Jun, L; Lormeau, JC; Van de Werf, F; Vanhove, P, 1995)
"The effect of chronic administration of variable low doses of Aspirin was studied on platelet adhesiveness, platelet count, bleeding time and clotting time to find out as to how low the dose of aspirin needs to be in order to have an effective antiplatelet effect in patients who require such therapy."	1.29	Effect of variable low doses of aspirin on platelet functions. ( Bose, S; Roohi, F; Shiralkar, M, 1994)
"Aspirin-treated dogs were not different from vehicle."	1.29	Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis. ( Cohen, DS; Dotson, R; Mathis, J; Olson, RW; Webb, RL, 1993)
"5 X SCa was administered with ASA plus heparin, time to occlusion was >180 minutes [T=0]."	1.29	The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. ( Feigen, LP; Frederick, LG; King, LW; Nicholson, NS; Salyers, AK; Suleymanov, OD, 1996)
"Aspirin use was found to be associated with less depression and anxiety or worry, as reported by the patient and as perceived by a significant other."	1.29	Is aspirin, as used for antithrombosis, an emotion-modulating agent? ( Brymer, J; Ketterer, MW; Kraft, P; Lovallo, WR; Rhoads, K, 1996)
"Inogatran-treated pigs showed a dose-dependent antithrombotic effect, and the average patency rates were 34 +/- 39, 54 +/- 37 and 80 +/- 32%, in groups 6, 7 and 8, respectively."	1.29	Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis. ( Grip, L; Mattsson, C; Rydén, L; Sjöquist, PO; Uriuda, Y; Wang, QD, 1996)
" There were significantly lower thromboxane B2 and 6-keto-PFG1a levels in the stenosed left arterior descending (LAD) segments with increasing dosage of aspirin-208 +/- 36, 24 +/- 31, 50 +/- 6 ng/g (P less than 0."	1.28	Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis. ( Benedict, CR; Buja, LM; Campbell, WB; Falinska, B; McNatt, J; Rosolowsky, M; Willerson, JT; Yao, SK, 1991)
"In 10 boys with coronary aneurysms following Kawasaki syndrome echocardiography was performed and compared to angiography with respect to its reliability in detecting coronary aneurysms."	1.28	[Coronary aneurysm following Kawasaki syndrome]. ( Engelhardt, W; Hofstetter, R; Keutel, J; Kluitmann, G; Mühler, E; Oberhoffer, R; von Bernuth, G, 1990)
"A higher recurrence rate after angioplasty is seen in the presence of a wall thrombus."	1.27	[Prevention of thrombosis in the after-care of coronary dilatation and thrombolysis]. ( Lorenz, RL; Schramm, W; Theisen, K; Weber, MA, 1986)

Research

Studies (549)

Authors

Clinical Trials (87)

Trial Overview

Trial Outcomes

Superiority on ISTH Major or CRNM Bleeding for Apixaban Versus VKA

Timeframe	Studies, this research(%)	All Research%
pre-1990	23 (4.19)	18.7374
1990's	138 (25.14)	18.2507
2000's	200 (36.43)	29.6817
2010's	172 (31.33)	24.3611
2020's	16 (2.91)	2.80

Authors	Studies
Chu, Y	2
Xu, Y	2
Wang, C	3
Yu, X	2
Ma, Q	2
Wang, H	2
Gorog, DA	1
Ferreiro, JL	2
Ahrens, I	1
Ako, J	2
Geisler, T	4
Halvorsen, S	1
Huber, K	1
Jeong, YH	3
Navarese, EP	1
Rubboli, A	2
Sibbing, D	2
Siller-Matula, JM	1
Storey, RF	3
Tan, JWC	1
Ten Berg, JM	8
Valgimigli, M	7
Vandenbriele, C	1
Lip, GYH	1
Zheng, Y	1
Lieschke, F	1
Schaefer, JH	1
Wang, X	2
Foerch, C	1
van Leyen, K	1
McGhie, D	1
Amos, D	1
Elder, A	1
Brieger, D	1
Lowe, HC	2
Lopes, RD	2
Leonardi, S	2
Wojdyla, DM	1
Vora, AN	2
Thomas, L	2
Vinereanu, D	1
Granger, CB	4
Goodman, SG	2
Aronson, R	2
Windecker, S	7
Thiele, H	2
Mehran, R	15
Alexander, JH	2
Rubin, GA	1
Kirtane, AJ	12
Chen, S	1
Redfors, B	1
Weisz, G	9
Baber, U	6
Zhang, Y	3
Stuckey, TD	7
Witzenbichler, B	10
Rinaldi, MJ	7
Neumann, FJ	9
Metzger, DC	7
Henry, TD	8
Cox, DA	6
Duffy, PL	6
Brodie, BR	7
Mazzaferri, EL	6
Ali, ZA	1
Ben-Yehuda, O	4
Stone, GW	12
Mangiacapra, F	1
Bressi, E	1
Colaiori, I	1
Ricottini, E	1
Cavallari, I	1
Capuano, M	1
Viscusi, MM	1
Spoto, S	1
Barbato, E	2
Di Sciascio, G	1
Lee, CH	1
Kim, U	1
García-Ropero, Á	1
Vargas-Delgado, AP	1
Santos-Gallego, CG	1
Badimon, JJ	4
Fox, KAA	1
Anand, SS	1
Aboyans, V	1
Cowie, MR	1
Debus, ES	1
Zeymer, U	3
Monje, D	1
Vogtländer, K	1
Lawatscheck, R	1
Gay, A	1
Peterson, BE	1
Bhatt, DL	6
Wojdyla, D	1
Siegel, AJ	1
Puram, RV	1
Erdil, RM	1
Weber, BN	1
Knelson, EH	1
Van Beuningen, AM	1
Wallwork, R	1
Gilyard, SN	1
Curtis, BR	1
Ranganathan, R	1
Leaf, RK	1
Malhotra, R	1
Natsuaki, M	1
Morimoto, T	1
Watanabe, H	2
Abe, M	1
Kawai, K	2
Nakao, K	1
Ando, K	1
Tanabe, K	1
Ikari, Y	3
Igarashi Hanaoka, K	1
Morino, Y	1
Kozuma, K	3
Kadota, K	1
Kimura, T	2
Chon, MK	1
Jung, SM	1
Lee, SY	2
Lee, SH	3
Hwang, KW	1
Choi, JH	2
Kim, JS	4
Park, YH	1
Kim, JH	3
Chun, KJ	1
Shoji, K	1
Zen, K	1
Ookura, T	1
Yanishi, K	1
Matoba, S	1
Streif, W	1
Faggioni, M	2
Sartori, S	3
Giustino, G	3
Cohen, DJ	5
Farhan, S	2
Ariti, C	3
Dangas, G	6
Gibson, M	1
Giacoppo, D	2
Krucoff, MW	4
Aquino, M	2
Chandrasekhar, J	2
Moliterno, DJ	8
Colombo, A	16
Vogel, B	2
Chieffo, A	4
Kini, AS	2
Steg, PG	9
Pocock, S	3
Nikolaou, NI	1
Secemsky, EA	2
Yeh, RW	4
Kereiakes, DJ	6
Cutlip, DE	6
Massaro, JM	4
Apruzzese, PK	2
Mauri, L	6
Ferrante, G	1
Condorelli, G	2
Pagnotta, P	2
Reimers, B	4
Felix, CM	1
Vlachojannis, GJ	1
IJsselmuiden, AJJ	1
Fam, JM	1
Smits, PC	2
Lansink, WJ	1
Diletti, R	2
Zijlstra, F	2
Regar, ES	1
Boersma, E	3
Onuma, Y	2
van Geuns, RJM	1
Didier, R	1
Morice, MC	3
Barragan, P	3
Noryani, AAL	1
Noor, HA	1
Majwal, T	1
Hovasse, T	1
Castellant, P	1
Schneeberger, M	1
Maillard, L	1
Bressolette, E	1
Wojcik, J	1
Delarche, N	2
Blanchard, D	1
Jouve, B	1
Ormezzano, O	2
Paganelli, F	2
Levy, G	1
Sainsous, J	1
Carrie, D	2
Furber, A	1
Berlan, J	1
Darremont, O	1
Le Breton, H	1
Lyuycx-Bore, A	1
Gommeaux, A	1
Cassat, C	1
Kermarrec, A	1
Cazaux, P	2
Druelles, P	1
Dauphin, R	1
Armengaud, J	1
Dupouy, P	2
Champagnac, D	1
Ohlmann, P	1
Ben Amer, H	1
Kiss, RG	2
Ungi, I	1
Gilard, M	2
Jiang, M	1
You, JHS	1
Litherland, C	2
Gurbel, PA	5
Généreux, P	3
Simonton, CA	2
Larsen, SB	1
Grove, EL	3
Neergaard-Petersen, S	1
Würtz, M	2
Hvas, AM	2
Kristensen, SD	3
Harada, Y	1
Michel, J	1
Lohaus, R	1
Mayer, K	2
Emmer, R	1
Lahmann, AL	1
Colleran, R	1
Wolk, A	1
Han, Y	1
Adriaenssens, T	1
Tölg, R	1
Seyfarth, M	2
Maeng, M	2
Zrenner, B	1
Jacobshagen, C	1
Wöhrle, J	1
Kufner, S	1
Morath, T	1
Ibrahim, T	1
Bernlochner, I	2
Fischer, M	1
Schunkert, H	2
Laugwitz, KL	2
Mehilli, J	1
Byrne, RA	2
Kastrati, A	2
Schulz-Schüpke, S	1
Piccolo, R	2
Feres, F	2
Abizaid, A	3
Hong, MK	7
Kim, HS	3
Palmerini, T	2
Ielasi, A	2
Campo, G	3
Rapetto, C	1
Varricchio, A	1
Cortese, B	2
Brugaletta, S	3
Geraci, S	1
Vicinelli, P	1
Scotto di Uccio, F	1
Secco, GG	1
Poli, A	1
Nicolini, E	1
Ishida, K	1
Latib, A	2
Tespili, M	1
Casella, G	1
Resciniti, E	1
Gallo, P	1
Xing, L	1
Yamamoto, E	1
Sugiyama, T	1
Jia, H	1
Ma, L	1
Hu, S	1
Zhu, Y	1
Li, L	2
Xu, M	1
Liu, H	1
Bryniarski, K	1
Hou, J	1
Zhang, S	1
Lee, H	1
Yu, B	1
Jang, IK	2
Jermini-Gianinazzi, I	1
Nascimento Silva, JS	1
de Barros, IML	1
Cantarelli, FL	1
Alves, RC	1
Falcão, FJA	1
Silva, JMDS	1
de Oliveira, FRA	1
Pedrosa, RP	1
Khan, SU	1
Talluri, S	1
Rahman, H	1
Lekkala, M	1
Khan, MS	2
Riaz, H	2
Shah, H	1
Kaluski, E	1
Sattur, S	1
Leggio, M	1
Fusco, A	1
Severi, P	1
Lombardi, M	1
Caldarone, E	1
D'Emidio, S	1
Armeni, M	1
Mereu, D	1
Bendini, MG	1
Mazza, A	1
Ueda, P	1
Jernberg, T	1
James, S	2
Alfredsson, J	1
Erlinge, D	1
Omerovic, E	1
Persson, J	1
Ravn-Fischer, A	1
Tornvall, P	1
Svennblad, B	1
Varenhorst, C	1
Greci, M	1
Russo, M	1
Pellegrino, A	1
Bassano, C	1
Nardi, P	1
Ruvolo, G	1
Brener, SJ	2
McAndrew, T	1
Myles, PS	2
Smith, JA	2
Kasza, J	2
Silbert, B	2
Jayarajah, M	2
Painter, T	2
Cooper, DJ	2
Marasco, S	2
McNeil, J	2
Bussières, JS	2
McGuinness, S	2
Chan, MTV	2
Wallace, S	2
Forbes, A	2
Byrne, K	1
Landoni, G	1
Dargham, BB	1
Baskar, A	1
Tejani, I	1
Cui, Z	1
Chauhan, S	1
Sum-Ping, J	1
Weideman, RA	1
Banerjee, S	1
Lim, GB	1
Kessler, T	1
Wolf, B	2
Eriksson, N	1
Kofink, D	1
Mahmoodi, BK	1
Rai, H	1
Tragante, V	1
Åkerblom, A	1
Becker, RC	2
Bopp, R	1
Katus, HA	2
Munz, M	1
Nordio, F	1
O'Donoghue, ML	1
Sager, HB	1
Solakov, L	1
Wobst, J	1
Asselbergs, FW	1
Erdmann, J	1
Koenig, W	1
Wallentin, L	2
Saad Shaukat, MH	1
Tatusov, A	1
Nappi, A	1
Yager, N	1
O'Brien, MP	1
Zafar, MU	1
Rodriguez, JC	1
Okoroafor, I	1
Heyison, A	1
Cavanagh, K	1
Rodriguez-Caprio, G	1
Weinberg, A	1
Escolar, G	1
Aberg, JA	1
Iwańczyk, S	1
Skorupski, W	1
Grygier, M	1
Sikora, T	1
Araszkiewicz, A	1
Lesiak, M	1
Rinfret, S	1
Rodés-Cabau, J	1
Bagur, R	1
Déry, JP	1
Dorais, M	1
Larose, E	1
Barbeau, G	1
Gleeton, O	1
Nguyen, CM	1
Noël, B	1
Proulx, G	1
Roy, L	1
Taillon, I	1
De Larochellière, R	1
Bertrand, OF	1
Puri, A	1
Saireddy, R	1
McClean, D	1
Echavarría-Pinto, M	1
Lopes, R	1
Gorgadze, T	1
Gonzalo, N	1
Hernández, R	1
Jiménez-Quevedo, P	2
Alfonso, F	4
Bañuelos, C	1
Nuñez-Gil, IJ	1
Ibañez, B	1
Fernández, C	2
Fernandez-Ortiz, A	4
García, E	1
Macaya, C	4
Escaned, J	1
Takeuchi, H	1
Park, J	1
Shin, DH	2
Kim, BK	2
Her, AY	2
Kim, YH	4
Choi, HH	1
Ko, YG	2
Choi, D	2
Jang, Y	2
Silva, MV	1
Dusse, LM	1
Vieira, LM	1
Carvalho, Md	1
Suh, SY	1
Kang, WC	1
Oh, PC	1
Choi, H	1
Moon, CI	1
Lee, K	1
Han, SH	1
Ahn, T	1
Choi, IS	1
Shin, EK	1
Park, KW	1
Kang, SH	1
Park, JJ	1
Yang, HM	1
Kang, HJ	1
Koo, BK	2
Park, BE	1
Cha, KS	1
Rhew, JY	1
Jeon, HK	1
Shin, ES	1
Oh, JH	1
Jeong, MH	5
Kim, S	1
Hwang, KK	1
Yoon, JH	2
Park, TH	1
Moon, KW	1
Kwon, HM	1
Chae, IH	2
Chen, Y	1
Tang, Y	1
Huang, X	1
Xie, Y	1
Brucculeri, F	1
Oppezzo, E	1
Taverna, GG	1
Dell'era, G	1
Demarchi, PG	1
Taverna, G	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int[NCT02415400]	Phase 4	4,614 participants (Actual)	Interventional	2015-06-04	Completed
Xarelto + Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients With Atherosclerosis. A Non-interventional Study[NCT03746275]		5,798 participants (Actual)	Observational	2018-11-13	Completed
A Prospective Evaluation of a Standardized Strategy for the Use of Bioresorbable Vascular Scaffold in ST-segment Elevation Myocardial Infarction: the BVS STEMI STRATEGY-IT Registry[NCT02601781]	Phase 4	500 participants (Actual)	Interventional	2015-10-31	Active, not recruiting
Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome[NCT02041650]	Phase 4	250 participants (Anticipated)	Interventional	2014-08-31	Completed
Telephone Contacts to Improve Adherence to Dual Anti-Platelet Therapy Following Drug-Eluting Stent Implantation; A Randomized Controlled-Trial[NCT01134679]		300 participants (Actual)	Interventional	2009-06-30	Completed
Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734]	Phase 4	3,750 participants (Anticipated)	Interventional	2010-06-30	Recruiting
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]	Phase 4	826 participants (Actual)	Interventional	2016-11-30	Completed
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128]		2,349 participants (Actual)	Observational	2008-08-31	Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]		1,492 participants (Anticipated)	Observational [Patient Registry]	2019-08-01	Recruiting
A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453]		1,516 participants (Actual)	Interventional	2008-07-31	Completed
The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940]		100 participants (Actual)	Interventional	2009-03-31	Completed
RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084]	Phase 4	2,292 participants (Actual)	Interventional	2008-04-30	Completed
PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957]	Phase 4	8,709 participants (Actual)	Interventional	2007-06-30	Completed
Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)[NCT00753753]		1,001 participants (Actual)	Observational	2008-02-29	Completed
EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Anti[NCT01069003]	Phase 4	2,272 participants (Actual)	Interventional	2010-04-30	Completed
A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions[NCT00180310]	Phase 3	300 participants (Actual)	Interventional	2005-07-31	Completed
SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions[NCT00402272]	Phase 4	2,700 participants (Actual)	Interventional	2006-11-30	Completed
SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions[NCT00180479]	Phase 3	1,002 participants (Actual)	Interventional	2005-06-30	Completed
A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions[NCT00496938]	Phase 4	1,600 participants (Actual)	Interventional	2007-07-31	Completed
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study[NCT00631228]		1,000 participants (Actual)	Observational	2008-06-30	Completed
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study[NCT00676520]		8,053 participants (Actual)	Observational	2008-07-31	Completed
SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions[NCT00307047]	Phase 3	3,687 participants (Actual)	Interventional	2006-08-31	Completed
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052]	Phase 4	634 participants (Anticipated)	Interventional	2021-07-02	Recruiting
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794]		8,575 participants (Actual)	Observational	2008-01-31	Completed
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938]	Phase 4	25,682 participants (Actual)	Interventional	2009-10-31	Completed
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127]		5,031 participants (Actual)	Observational	2009-06-30	Completed
Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281]		1,079 participants (Actual)	Interventional	2010-10-31	Completed
Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel[NCT00398463]	Phase 4	263 participants (Actual)	Interventional	2006-05-31	Completed
A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725]	Phase 3	0 participants (Actual)	Interventional		Withdrawn (stopped due to Study was not initiated, change in clinical development)
Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing[NCT01477775]	Phase 4	4,000 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent[NCT01261832]	Phase 4	951 participants (Anticipated)	Interventional	2011-07-31	Active, not recruiting
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547]		88 participants (Actual)	Observational	2018-01-01	Completed
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273]		1,800 participants (Anticipated)	Observational [Patient Registry]	2018-11-21	Not yet recruiting
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374]	Phase 4	300 participants (Anticipated)	Interventional	2015-05-31	Recruiting
Efficacy and Safety of Anticoagulant on Early Treatment of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03764241]	Phase 3	280 participants (Anticipated)	Interventional	2020-02-01	Recruiting
Efficacy and Safety of Anticoagulant on Early Prevention of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03786757]	Phase 3	200 participants (Anticipated)	Interventional	2019-04-01	Not yet recruiting
The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).[NCT01012544]	Phase 4	187 participants (Actual)	Interventional	2009-04-30	Completed
Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411]	Phase 4	2,500 participants (Actual)	Interventional	2009-01-31	Completed
Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785]		90 participants (Actual)	Observational	2017-03-27	Completed
Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling[NCT02224131]	Phase 4	1,856 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry[NCT01824147]		400 participants (Actual)	Observational	2013-08-31	Completed
ABSORB II RANDOMIZED CONTROLLED TRIAL A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Sub[NCT01425281]		501 participants (Actual)	Interventional	2011-11-30	Completed
French Observatory Evaluating the Use of Intracoronary Prosthesis ABSORB BVS[NCT02238054]		2,072 participants (Actual)	Observational [Patient Registry]	2014-09-30	Completed
Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966]	Phase 3	3,602 participants (Actual)	Interventional	2005-03-31	Completed
A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers[NCT01557335]	Phase 1	30 participants (Actual)	Interventional	2010-11-30	Completed
Randomized Clinical Comparative Study of the Nobori and the Cypher Stents in Unselected Subjects With Ischemic Heart Disease[NCT01254981]	Phase 4	2,504 participants (Actual)	Interventional	2009-07-31	Completed
Comparison of the Everolimus Eluting (XIENCE-V®, XIENCE-Prime® or PROMUS® Stent) With the Biolimus A9 Eluting NOBORI® Stent in All-comers: a Randomized Open Label Study[NCT01233453]	Phase 4	2,700 participants (Anticipated)	Interventional	2009-01-31	Active, not recruiting
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465]	Phase 4	50 participants (Actual)	Interventional	2017-02-16	Completed
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802]		120 participants (Anticipated)	Interventional	2014-08-31	Not yet recruiting
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372]	Phase 4	150 participants (Actual)	Interventional	2007-09-30	Completed
Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186]	Phase 4	190 participants (Anticipated)	Interventional	2010-06-30	Active, not recruiting
Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535]	Phase 4	200 participants (Anticipated)	Interventional	2005-03-31	Recruiting
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671]	Phase 4	20 participants (Actual)	Interventional	2009-06-30	Completed
Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693]	Phase 4	80 participants (Actual)	Interventional	2008-11-30	Completed
Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612]	Phase 3	200 participants (Actual)	Interventional	2005-06-30	Completed
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817]	Phase 4	20 participants (Actual)	Interventional	2016-06-26	Completed
Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301]		100 participants (Anticipated)	Observational	2015-09-30	Not yet recruiting
Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428]		159 participants (Actual)	Interventional	2006-05-31	Completed
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044]	Phase 3	30 participants (Anticipated)	Interventional	2009-04-30	Recruiting
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435]		889 participants (Actual)	Interventional	2013-06-30	Terminated (stopped due to Ethics Committe decision)
Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)[NCT00373451]	Phase 4	1,721 participants (Actual)	Interventional	2006-07-31	Completed
Infliximab (Remicade®) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease[NCT00760435]	Phase 3	196 participants (Actual)	Interventional	2009-03-31	Completed
Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556]		179 participants (Actual)	Interventional	2003-01-31	Completed
Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study[NCT01239654]	Phase 3	60 participants (Actual)	Interventional	2010-09-30	Completed
A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145]	Phase 4	30 participants (Anticipated)	Interventional	2007-11-30	Completed
In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030]	Phase 4	77 participants (Anticipated)	Interventional	2006-08-31	Recruiting
The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204]		60 participants (Actual)	Interventional	2008-05-31	Completed
Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837]		33 participants (Actual)	Observational	2014-12-31	Completed
Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).[NCT00704561]		44 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507]	Phase 4	60 participants (Actual)	Interventional	2012-04-30	Completed
Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913]	Phase 3	300 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265]		31 participants (Actual)	Interventional	2014-09-30	Completed
Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894]		0 participants (Actual)	Observational	2010-11-30	Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.)
Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949]		8 participants (Actual)	Interventional	2013-09-30	Completed
PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720]	Phase 3	3,400 participants (Anticipated)	Interventional	2020-10-15	Recruiting
Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591]		300 participants	Interventional	2001-04-30	Active, not recruiting
A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome[NCT05657860]	Phase 4	33 participants (Anticipated)	Interventional	2020-12-17	Recruiting
An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant Depression[NCT05615948]	Phase 4	20 participants (Anticipated)	Interventional	2022-12-06	Recruiting
French Registry to Evaluate the Safety and Efficacy of the Diamondback 360TM Orbital Atherectomy System in the Preparation of Calcified Coronary Lesions Before Implantation of a Coronary Endoprothesis[NCT05417022]		300 participants (Anticipated)	Observational [Patient Registry]	2022-06-15	Recruiting
Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.[NCT00380809]	Phase 4	240 participants (Actual)	Interventional	2006-08-31	Completed
A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401]	Phase 3	2,399 participants (Actual)	Interventional	1996-07-31	Completed
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003]	Phase 4	2,022 participants (Actual)	Interventional	2003-03-31	Completed
Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250]	Phase 4	800 participants (Actual)	Interventional	2003-06-30	Completed
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465]	Phase 4	60 participants (Actual)	Interventional	2004-10-31	Completed
Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309]		30 participants (Anticipated)	Interventional	2006-04-30	Completed
A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175]		1,960 participants (Actual)	Interventional	2013-01-16	Terminated (stopped due to Slow enrollment)
[NCT00000500]	Phase 3	0 participants	Interventional	1981-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Time to first occurrence during the time the participants were treated with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

The Composite Endpoints of Death and Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Aspirin Versus no Aspirin

Intervention	Percentage per year (Number)
Apixaban	24.66
Vitamin K Antagonist	35.79

"Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

The Rate of All-cause Death or All-cause Rehospitalization With Apixaban Versus VKA

Intervention	Percentage per year (Number)
Acetylsalicylic Acid Film Coated Tablet	15.28
Placebo Matching Acetylsalicylic Acid Film Coated Tablet	17.73

"Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

The Rate of All-cause Death or All-cause Rehospitalization With Aspirn Versus no Aspirin

Intervention	Percentage per year (Number)
Apixaban	57.24
Vitamin K Antagonist	69.19

"Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist (VKA) During the Treatment Period

Intervention	Percentage per year (Number)
Acetylsalicylic Acid Film Coated Tablet	65.72
Placebo Matching Acetylsalicylic Acid Film Coated Tablet	60.56

"Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

The Rate of ISTH Major or CRNM Bleeding With Aspirin Versus no Aspirin During the Treatment Period

Intervention	Percentage per year (Number)
Apixaban	24.66
Vitamin K Antagonist	35.79

"Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo.~N is the number of participants with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

The Rate of the Composite Endpoint of Death or Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Apixaban Versus VKA

Intervention	Percentage per year (Number)
Acetylsalicylic Acid Film Coated Tablet	40.51
Placebo Matching Acetylsalicylic Acid Film Coated Tablet	21.03

"Time to first occurrence during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

Composite Endpoint of Cardiac Death and Myocardial Infarction (Not Clearly Attributable to a Non-target Vessel)

Overall Stent Thrombosis, Defined as Definite and Probable Stent Thrombosis, According to the Academic Research Consortium (ARC) Definition

Death

Major Adverse Cardiac Event (MACE)

Intervention	Percentage per year (Number)
Apixaban	15.85
Vitamin K Antagonist	17.17

Intervention	percentage of participants (Number)
Cardiac Death or Target Vessel MI	4.2

Intervention	percentage of participants (Number)
Overall Stent Thrombosis (Definite and Probable-ARC)	0.9

Intervention	percentage of participants (Number)
Primary Enrollment Group	1.3

Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Stent Thrombosis (ST)

Intervention	percentage of participants (Number)
Primary Enrollment Group	5.5

Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months

Target Lesion Failure (TLF)

Intervention	percentage of participants (Number)
Primary Enrollment Group	0.1

Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months

Target Vessel Failure (TVF)

Intervention	percentage of participants (Number)
Primary Enrollment Group	4.7

Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Target Vessel MI

Intervention	percentage of participants (Number)
Primary Enrollment Group	6.3

Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months

In-stent Late Lumen Loss (LLL)

Intervention	percentage of eligible participants (Number)
Primary Enrollment Group	1.4

The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months

Percent of Patient With Target Lesion Failure(Major Secondary Endpoint)

Intervention	mm (Mean)
Zotarolimus Eluting Stent	0.13

Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months

In-Stent Percent Diameter Stenosis

Intervention	percentage of participants with TLF (Number)
Zotarolims Eluting Stent	4.0

In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months

Target Lesion Failure

Intervention	Percentage diameter stenosis (Mean)
1. Resolute - 12-13 Months	21.65
2. XIENCE V - 12-13 Months	19.76

Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months

To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation

Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions

Intervention	percentage of participants (Number)
1. Resolute - 12-13 Months	8.2
2. XIENCE V - 12-13 Months	8.3

Intervention	participants (Number)
E-ZES	61
C-SES	75

Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years

Incidence of Major Bleeding (GUSTO Classification, Severe and Moderate Bleeding Combined) for Randomized Subjects

Intervention	participants (Number)
	Total death and large non-fatal myocardial infarct	Total death and non-fatal myocardial infarctions	Cardiac death and large non-fatal MI	Cardiac death and non-fatal MI	Target lesion revascularization	Stroke	Bleeding events
C-SES	255	360	174	282	156	72	184
E-ZES	225	331	157	265	249	77	201

(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

Percentage of Participants of Incidence of ARC Definite or Probable Stent Thrombosis (ST) for Randomized Subjects

Intervention	Percentage of participants (Number)
Placebo Arm	1.8
Thienopyridine Therapy	2.0
Surveillance Arm	4.8

"All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)~Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers~Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

Percentage of Participants With Composite of All Death, Target Vessel Myocardial Infarction (MI) and Stroke (Defined as MACCE) for Randomized Subjects

Intervention	percentage of participants (Number)
Placebo Arm	1.0
Thienopyridine Therapy	0.5
Surveillance Arm	2.4

(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

% Volume Obstruction (% VO)

Intervention	Percentage of participants (Number)
Placebo Arm	4.3
Thienopyridine Therapy	4.8
Surveillance Arm	16.9

Defined as stent intimal hyperplasia and calculated as 100*(Stent Volume - Lumen Volume)/Stent Volume by IVUS. (NCT00180479)
Timeframe: at 240 days

Acute Success: Clinical Device

Intervention	percent of volume obstruction (Mean)
XIENCE V® EECSS	6.91
TAXUS® EXPRESS2™ ECSS	11.21

Successful delivery and deployment of 1st implanted study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital

Acute Success: Clinical Procedure

Intervention	percentage of participants (Number)
XIENCE V® EECSS	98.3
TAXUS® EXPRESS2™ ECSS	98.7

Successful delivery and deployment of study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital

Distal Late Loss

Intervention	percentage of participants (Number)
XIENCE V® EECSS	98.5
TAXUS® EXPRESS2™ ECSS	97.3

Distal MLD post-procedure minus distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement) (NCT00180479)
Timeframe: 240 days

In-segment % Angiographic Binary Restenosis (% ABR) Rate

Intervention	millimeters (Mean)
XIENCE V® EECSS	0.09
TAXUS® EXPRESS2™ ECSS	0.10

Percent of subjects with a follow-up in-segment percent diameter stenosis of ≥ 50% per QCA (NCT00180479)
Timeframe: 240 days

In-segment % Diameter Stenosis (% DS)

Intervention	percentage of participants (Number)
XIENCE V® EECSS	4.7
TAXUS® EXPRESS2™ ECSS	8.9

Within the margins of the stent, 5 mm proximal and 5 mm distal to the stent, the value calculated as 100 * (1 - in-segment MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: 240 days

In-stent % Angiographic Binary Restenosis (% ABR) Rate

Intervention	percent of in-segment diameter stenosis (Mean)
XIENCE V® EECSS	18.77
TAXUS® EXPRESS2™ ECSS	22.82

Percent of subjects with a follow-up in-stent percent diameter stenosis of ≥ 50% per quantitative coronary angiography (QCA) (NCT00180479)
Timeframe: at 240 days

In-stent % Diameter Stenosis (% DS)

Intervention	percentage of participants (Number)
XIENCE V® EECSS	2.3
TAXUS® EXPRESS2™ ECSS	5.7

In-stent: Within the margins of the stent, the value calculated as 100 * (1 - in-stent MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: at 240 days

In-stent Late Loss

Intervention	percent diameter stenosis (Mean)
XIENCE V® EECSS	5.92
TAXUS® EXPRESS2™ ECSS	10.30

In-stent MLD post-procedure minus in-stent MLD at follow-up (in-stent defined as within the margins of the stent) (NCT00180479)
Timeframe: at 240 days

Ischemia Driven Major Adverse Cardiac Event (MACE)

Intervention	millimeters (Mean)
XIENCE V® EECSS	0.16
TAXUS® EXPRESS2™ ECSS	0.30

"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 1 year

Ischemia Driven Major Adverse Cardiac Event (MACE)

Intervention	percentage of participants (Number)
XIENCE V® EECSS	6.0
TAXUS® EXPRESS2™ ECSS	10.3

Intervention	percentage of participants (Number)
XIENCE V® EECSS	2.9
TAXUS® EXPRESS2™ ECSS	5.2

Intervention	percentage of participants (Number)
XIENCE V® EECSS	5.0
TAXUS® EXPRESS2™ ECSS	8.8

Intervention	percentage of participants (Number)
XIENCE V® EECSS	9.7
TAXUS® EXPRESS2™ ECSS	16.4

Intervention	percentage of participants (Number)
XIENCE V® EECSS	1.3
TAXUS® EXPRESS2™ ECSS	3.0

Intervention	percentage of participants (Number)
XIENCE V® EECSS	12.8
TAXUS® EXPRESS2™ ECSS	18.5

Ischemia Driven Major Adverse Cardiac Event(MACE)

Intervention	percentage of participants (Number)
XIENCE V® EECSS	14.4
TAXUS® EXPRESS2™ ECSS	22.0

Ischemia Driven Target Lesion Revascularization (ID-TLR)

Intervention	percentage of participants (Number)
XIENCE V® EECSS	7.7
TAXUS® EXPRESS2™ ECSS	13.8

"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 1 years

Ischemia Driven Target Lesion Revascularization (ID-TLR)

Intervention	percentage of participants (Number)
XIENCE V® EECSS	3.4
TAXUS® EXPRESS2™ ECSS	5.6

Intervention	percentage of participants (Number)
XIENCE V® EECSS	1.5
TAXUS® EXPRESS2™ ECSS	2.1

Intervention	percentage of participants (Number)
XIENCE V® EECSS	5.7
TAXUS® EXPRESS2™ ECSS	9.2

Intervention	percentage of participants (Number)
XIENCE V® EECSS	2.7
TAXUS® EXPRESS2™ ECSS	5.0

Intervention	percentage of participants (Number)
XIENCE V® EECSS	5.7
TAXUS® EXPRESS2™ ECSS	9.2

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 1 year

Ischemia Driven Target Vessel Revascularization (ID-TVR)

Major Secondary Endpoint: Ischemia Driven Target Vessel Failure (ID-TVF)

"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 270 days

Persisting Incomplete Stent Apposition, Late-acquired Incomplete Stent Apposition, Aneurysm, Thrombosis, and Persisting Dissection

"Incomplete Apposition (Persisting & Late acquired): Failure to completely appose vessel wall w/ ≥1 strut separated from vessel wall w/ blood behind strut per ultrasound. Aneurysm: Abnormal vessel expansion ≥ 1.5 of reference vessel diameter. Thrombus: Protocol & ARC definition.~Persisting dissection @ follow-up, present post-procedure." (NCT00180479)
Timeframe: at 240 days

Primary Endpoint: In-segment Late Loss (LL)

In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment. (NCT00180479)
Timeframe: 240 days

Proximal Late Loss

Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement) (NCT00180479)
Timeframe: at 240 days

Target Vessel Failure (TVF)

Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Clinical Device Success

Composite Rate of All Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Composite Rate of All Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Composite Rate of All Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Composite Rate of All Death, Any MI (Q-wave and Non Q-wave) and Any Repeat Revascularization (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Composite Rate of All Death, Any MI (Q-wave and Non Q-wave) and Any Repeat Revascularization (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Composite Rate of All Death, Any MI (Q-wave and Non Q-wave) and Any Repeat Revascularization (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Composite Rate of Cardiac Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Composite Rate of Cardiac Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Composite Rate of Cardiac Death and Any Myocardial Infarction (MI)

Composite Rate of Cardiac Death and MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Clinically-indicated Target Lesion Revascularization (CI-TLR) (PCI and CABG) (This Composite Endpoint is Also Denoted as TLF)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Composite Rate of Cardiac Death, Any MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Target Lesion Revascularization (TLR) (PCI and CABG)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Composite Rate of Cardiac Death, Any MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Target Lesion Revascularization (TLR) (PCI and CABG)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Composite Rate of Cardiac Death, Any MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Target Lesion Revascularization (TLR) (PCI and CABG)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Death (Cardiac Death, Vascular Death, and Non-cardiovascular Death)

Dual Antiplatelet Medication Usage

"Patient is included if medications (both aspirin and thienopyridine) were taken for at least 1 day during the visit window. The visit window for 14-day visit is 7-21 days, 30-day visit is 23-37 days, 180-day visit is 166-194 days, 1-year visit is 323-407 days, and 2-year visit is 688-772 days.~Adjunctive antiplatelet therapy includes: Aspirin & Thienopyridines (Clopidogrel/Ticlopidine/Prasugrel).~Compliance refers to subjects following prescribed instructions for taking these medications. Therapy interruptions refer to any intervals during which the subject stops taking one or all of the prescribed medications." (NCT00676520)
Timeframe: at 1 year

Dual Antiplatelet Medication Usage

Dual Antiplatelet Therapy Non-compliance Through 1 Year

Defined as patients who had at least 1 day without using either aspirin or thienopyridine from 1 to 407 days post index procedure. (NCT00676520)
Timeframe: 1 year

Major Bleeding Complications

Patient Health Status, Physical Limitations Assessed Using the SAQ (Seattle Angina Questionaire)

"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: at 1 year

Patient Health Status, Physical Limitations Assessed Using the SAQ (Seattle Angina Questionaire)

Procedural Success

Revascularization (Target Lesion, Target Vessel [TVR], and Non-target Vessel) (PCI and CABG)

SAQ (Seattle Angina Questionaire)

Stent Thrombosis (Definite and Probable) Rate as Defined by ARC (Academic Research Constortium).

"ARC Defines Stent Thrombosis in the following way:~Definite Stent Thrombosis: Angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region AND at least ONE of the following, additional criteria:~Acute ischemic symptoms Ischemic ECG changes Elevated cardiac biomarkers~Probable Stent Thrombosis: Any unexplained death within 30 days of stent implantation or any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause~Possible Stent Thrombosis Any unexplained death beyond 30 days~For further information on ARC definitions, please refer to the following website: http://circ.ahajournals.org/content/115/17/2344.full#sec-1" (NCT00676520)
Timeframe: up to 1 year

Acute Success (Clinical Device)

Successful delivery and deployment of the first implanted study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stents) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable). Bailout subjects will be included as device success only if the above criteria for clinical device are met. (NCT00307047)
Timeframe: Acute: At time of index procedure

Acute Success (Clinical Procedure)

Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days following the index procedure. In multiple lesion setting all lesions must meet clinical procedure success. (NCT00307047)
Timeframe: Acute: At time of index procedure

All Cause Mortality

All MI

All Myocardial Infarction (MI)

Cardiac Death or Target Vessel MI Rate

Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)

Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition

"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 0-30 days

Definite + Probable Stent Thrombosis Rate Based on ARC Definition

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 1 years

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 180 days

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 2 years

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 270 days

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 3 years

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 30 days

Ischemia Driven Target Lesion Failure (TLF)

Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 1 year

Ischemia Driven Target Lesion Failure (TLF)

Ischemia Driven Target Lesion Revascularization (TLR)

"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 1 year

Ischemia Driven Target Lesion Revascularization (TLR)

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 1 year

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 180 days

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 2 years

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 270 days

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 3 years

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 30 days

Ischemia Driven Target Vessel Revascularization (TVR)

"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 1 year

Ischemia Driven Target Vessel Revascularization (TVR)

Protocol Defined Stent Thrombosis Rate

"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 0-1123 days

Protocol Defined Stent Thrombosis Rate

Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Absolute Difference (3 Years Post Nitrate- 3 Years Pre Nitrate) In-Scaffold Mean Lumen Diameter (MLD)

In-scaffold:Within the margins of the scaffold. (NCT01425281)
Timeframe: 3 years

Absolute Difference (3 Years Post-nitrate - Post Procedure Post-nitrate) In-Scaffold Minimum Lumen Diameter

In-scaffold:Within the margins of the scaffold. (NCT01425281)
Timeframe: 3 years

Device Success

Successful delivery and deployment of the first study scaffold/stent the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 50% by quantitative coronary angiography (QCA). (NCT01425281)
Timeframe: From the start of index procedure to end of index procedure

Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)

"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 1 year

Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)

"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 4 years

Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)

"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 5 years

Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)

"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)

Number of Participants Experiencing All Death/All MI

"All deaths includes~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI Development of new, pathological Q wave on the ECG.~Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 180 days

Number of Participants Experiencing All Death/All MI

"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 4 years

Number of Participants Experiencing All Death/All MI

"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 2 years

Number of Participants Experiencing All Death/All MI

"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 3 years

Number of Participants Experiencing All Death/All MI

"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI)~Q wave MI Development of new, pathological Q wave on the ECG.~Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 5 years

Number of Participants Experiencing All Death/All MI

"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)

Number of Participants Experiencing All Death/All MI

"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 1 year

Number of Participants Experiencing Cardiac Death/All MI

"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 4 years

Number of Participants Experiencing Cardiac Death/All MI

"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 1 year

Number of Participants Experiencing Cardiac Death/All MI

"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 180 days

Number of Participants Experiencing Cardiac Death/All MI

"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 2 years

Number of Participants Experiencing Cardiac Death/All MI

"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 3 years

Number of Participants Experiencing Cardiac Death/All MI

"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 30 days

Number of Participants With All Myocardial Infarction (Per Protocol Definition)

"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 1 year

Number of Participants With All Myocardial Infarction (Per Protocol Definition)

"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of Creatine kinase (CK) levels to ≥ two times the upper limit of normal (ULN) with elevated Creatine kinase-MB (CK-MB) in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 30 days

Number of Participants With All Myocardial Infarction (Per Protocol Definition)

"Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 4 years

Number of Participants With All Myocardial Infarction (Per Protocol Definition)

Number of Participants With All Revascularization

"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 1 year

Number of Participants With All Revascularization

Revascularization: Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold. Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion. Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion. Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 5 years

Number of Participants With DMR (All Death, All MI, All Revascularization)

DMR is the composite of All Death, All MI, All Revascularization (NCT01425281)
Timeframe: 4 years

Number of Participants With DMR (All Death, All MI, All Revascularization)

DMR is the composite of All Death, All MI, All Revascularization (NCT01425281)
Timeframe: 5 years

Number of Participants With DMR (All Death, All MI, All Revascularization)

DMR is the composite of All Death, All MI, All Revascularization (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)

Number of Participants With DMR (All Death, All MI, All Revascularization)

DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 1 year

Number of Participants With DMR (All Death, All MI, All Revascularization)

DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 180 days

Number of Participants With DMR (All Death, All MI, All Revascularization)

DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 2 years

Number of Participants With DMR (All Death, All MI, All Revascularization)

DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 3 years

Number of Participants With DMR (All Death, All MI, All Revascularization)

DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 30 days

Number of Participants With Major Adverse Cardiac Events (MACE) (Cardiac Death, All MI, ID-TLR)

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 1 year

Number of Participants With Major Adverse Cardiac Events (MACE) (Cardiac Death, All MI, ID-TLR)

Number of Participants With Non Target Vessel Revascularization (Non-TVR)

Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 1 year

Number of Participants With Non Target Vessel Revascularization (Non-TVR)

Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 180 days

Number of Participants With Non Target Vessel Revascularization (Non-TVR)

Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 2 years

Number of Participants With Non Target Vessel Revascularization (Non-TVR)

Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 3 years

Number of Participants With Non Target Vessel Revascularization (Non-TVR)

Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 30 days

Number of Participants With Non Target Vessel Revascularization (Non-TVR)

Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 4 years

Number of Participants With Non Target Vessel Revascularization (Non-TVR)

Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)

Number of Participants With Non-Target Vessel Revascularization (Non-TVR)

Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 5 years

Number of Participants With Procedural Success

Achievement of final in-scaffold/stent residual stenosis of less than 50% by QCA with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay. (NCT01425281)
Timeframe: From the start of index procedure to end of index procedure

Number of Participants With Target Lesion Failure (TLF) (Cardiac Death, Target Vessel Myocardial Infarction (TV-MI), ID-TLR)

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 30 days

Number of Participants With Target Lesion Failure (TLF) (Cardiac Death, TV-MI, ID-TLR)

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 1 year

Number of Participants With Target Lesion Failure (TLF) (Cardiac Death, TV-MI, ID-TLR)

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 180 days

Number of Participants With Target Lesion Failure (TLF) (Cardiac Death, TV-MI, ID-TLR)

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 2 years

Number of Participants With Target Lesion Failure (TLF) (Cardiac Death, TV-MI, ID-TLR)

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 3 years

Number of Participants With Target Lesion Failure (TLF) (Cardiac Death, TV-MI, ID-TLR)

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 4 years

Number of Participants With Target Lesion Failure (TLF) (Cardiac Death, TV-MI, ID-TLR)

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 5 years

Number of Participants With Target Lesion Failure (TLF) (Cardiac Death,(Target Vessel Myocardial Infarction(TV-MI), ID-TLR)

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)

Number of Participants With Target Lesion Revascularization (TLR)

"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated (CI) or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 30 days

Number of Participants With Target Lesion Revascularization (TLR)

"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 1 year

Number of Participants With Target Lesion Revascularization (TLR)

"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 180 days

Number of Participants With Target Lesion Revascularization (TLR)

"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 2 years

Number of Participants With Target Lesion Revascularization (TLR)

"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 3 years

Number of Participants With Target Lesion Revascularization (TLR)

"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 4 years

Number of Participants With Target Lesion Revascularization (TLR)

"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 5 years